Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 4/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 4/20 | 0.40 |
| ▸ | F12 | P00748 | 3/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18998164 | 0.89 | KRAS (0.49) | KRASALDH1A1TSHRSMN1; SMN2NR3C1 | |
| SCHEMBL18997607 | 0.84 | KRAS (0.50) | KRASALDH1A1F12TSHRSMN1; SMN2 | |
| SCHEMBL18997601 | 0.83 | KRAS (0.54) | KRASALDH1A1NPSR1F12TSHR | |
| SCHEMBL18997596 | 0.82 | KRAS (0.46) | KRASALDH1A1TSHR | |
| SCHEMBL18998165 | 0.81 | KRAS (0.70) | KRASTSHRSMN1; SMN2 | |
| SCHEMBL18997610 | 0.80 | KRAS (0.46) | KRASALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL23222305 | 0.79 | TDP1 (0.47) | ALDH1A1NPSR1TSHRSMN1; SMN2 | |
| SCHEMBL18997609 | 0.76 | KRAS (0.44) | KRASALDH1A1NPSR1TSHRSMN1; SMN2 | |
| SCHEMBL18997599 | 0.75 | KRAS (0.43) | KRASALDH1A1F12TSHRSMN1; SMN2 | |
| SCHEMBL19049556 | 0.75 | KRAS (0.46) | KRASALDH1A1PDK1PDK2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | KRAS 608/4885ALDH1A1 2765/4885NPSR1 3909/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | KRAS 2/4885ALDH1A1 3448/4885NPSR1 4353/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | KRAS 608/4885ALDH1A1 2765/4885NPSR1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.